On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved Darolutamide for de novo metastatic castration-sensitive prostate cancer (mCSPC), marking a notable advancement in prostate cancer care. This post delves into the data behind this Darolutamide FDA Approval 2025, its implications, and its significance for oncologists and researchers. Advertisement A 10-Year Evolution of … Continue reading FDA Approves Darolutamide for mCSPC Prostate Cancer